Pioneering diagnostics
E.g., 25/05/2013
E.g., 25/05/2013
PreviousNext

Nicolas Cartier appointed Corporate Vice President, Industrial Microbiology Unit of bioMérieux

Marcy l’Etoile, France, May 21, 2013 — A major player in the field of in vitro diagnostics and world leader in industrial microbiology, bioMérieux has announced the appointment of Nicolas Cartier as Corporate Vice President, Industrial Microbiology Unit, effective starting today.

21 May, 2013

Before joining bioMérieux, Nicolas Cartier, spent most of his professional career at Sanofi. Since 2009, he has been General Manager of Sanofi France, the Group’s second largest affiliate. Prior to that, he gained 10 years’ international experience through various roles in...

bioMérieux - First-Quarter 2013 Business Review

23 April, 2013

  • Stable sales in a persistently difficult European economy
  • 2013 objective of 3-5% organic sales growth maintained
    • Solid commercial negotiations underway
    • Confirmed favorable growth...

Veolia Environnement and bioMérieux initiate a research partnership to develop an innovative monitoring system for drinking water quality

25 March, 2013

Paris, Lyon, March 25, 2013 – At BIOVISION, the world life sciences forum, Veolia Environnement, global leader in water services and expert in environmental services, and bioMérieux, global player in in vitro diagnostic solutions and world leader in industrial microbiology,...

bioMérieux - 2012 Financial Results

13 March, 2013

2012 performance: objectives met

  • Sales up 6.8% at constant exchange rates
  • €260 million in operating income before non-recurring items
  • €134 million in free cash flow
  • Robust...

2012 Business Review & Investor Day

23 January, 2013

2012 Business Review

  • Sales up 6.8% at constant exchange rates, in line with targets for the year

Investor Day

  • Innovation and...

bioMérieux Opens a Subsidiary in Vietnam, Strengthening its Footprint in High-growth Southeast Asia

04 December, 2012

Marcy l’Etoile, France – bioMérieux, a world leader in the field of in vitro diagnostics, announces the opening of its 41st commercial subsidiary in Hanoi, Vietnam. This wholly owned company in Vietnam will be bioMérieux’s 7th subsidiary in Southeast Asian...

bioMérieux and Quanterix Sign Strategic Partnership in Ultrasensitive and Multiplex Immunoassays

Quanterix’s Simoa™ technology to be developed for diagnostic applications.bioMérieux gains exclusive rights for clinical laboratories and industrial applications.bioMérieux takes equity stake in Quanterix and leads Series C financing round.

15 November, 2012

Marcy l’Etoile (France) and Lexington, MA (U.S.)  —
bioMérieux and Quanterix announced today that they have entered into a strategic agreement that gives bioMérieux worldwide exclusive rights to Quanterix’s Simoa technology in clinical laboratories and for industrial...

VIDAS® 3, the New-generation VIDAS®

VIDAS® 3, the New-generation VIDAS® Presented at the JIB International Biologists Congress

07 November, 2012

Marcy L'Étoile, France, November 7, 2012 — bioMérieux, a world leader in the field of in vitro diagnostics, presented today VIDAS® 3, the new generation of its automated immunoassay system, during the Journées Internationales de Biologie (JIB) congress in Paris...

Dr. Mark Miller joins bioMérieux as Chief Medical Officer

World-leading expert on infectious disease prevention and control to enhance medical value of bioMérieux’s solutions

31 October, 2012

Marcy l'Étoile, France — bioMérieux, a world leader in in vitro diagnostics, announces the arrival of Dr. Mark Miller in the newly created role of Chief Medical Officer. Dr. Miller is also a member of the bioMérieux Management Committee and heads the Company’s...

bioMérieux - Business Review for the nine months ended September 30, 2012

23 October, 2012

Sales

  • Up 7.5% at constant exchange rates
  • Of which 3.2%* organic growth

Confirmed strong momentum in emerging markets

  • 28% of consolidated sales
  • ...

PreviousNext